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Background: The calpains are intracellular cysteine proteases that function in a variety of important cellular
functions, including signalling, motility, apoptosis and survival. In breast cancer high calpain-1 and calpain-2
expression has been associated with adverse clinical outcome. Calpain-9 was thought to be exclusively expressed in
the digestive tract; however recent studies have shown that this protein is also expressed in breast tissue.
Methods: We investigated the expression of calpain-9 in a large cohort of early stage breast cancer patients
(n = 783) using immunohistochemistry on a tissue microarray. Patients had long-term follow-up information
available for analysis.
Results: Low expression of calpain-9 was associated with patients over 40 years of age (P = 0.025), smaller tumour
size (P = 0.001), lower tumour stage (P = 0.009), a more favourable Nottingham Prognostic Index value (P = 0.002)
and positive oestrogen receptor status (P = 0.014). Calpain-9 expression was not associated with survival in the total
patient cohort, however low calpain-9 expression was associated with adverse survival in patients who received
endocrine therapy (P = 0.033), which remained significant in multivariate Cox regression analysis accounting for
potential confounding factors (hazard ratio (HR) = 0.56, 95% confidence interval (95% CI) = 0.36-0.89, P = 0.013).
Low calpain-9 expression was also associated with adverse survival in patients with an intermediate Nottingham
Prognostic Index value (P = 0.009), and remained so in multivariate analysis (HR = 0.54, 95% CI = 0.36-0.82, P = 0.003).
Conclusions: This study suggests that calpain-9 may play a role in breast cancer and that low expression is
associated with poorer patient clinical outcome following endocrine therapy. Validation studies are warranted as
determining expression of calpain-9 may provide important prognostic information.
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Breast cancer is a heterogeneous disease; one major
factor of disease heterogeneity is tumour expression of the
oestrogen receptor (ER). ER positive breast cancers can be
treated using endocrine therapies including aromatase
inhibitors that inhibit oestrogen synthesis, such as exe-
mestane, letrozole and anastrozole, in post-menopausal* Correspondence: sarah.storr@nottingham.ac.uk
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unless otherwise stated.women and selective ER modulators that compete with
oestrogen for receptor binding, such as tamoxifen, in both
post-menopausal and pre-menopausal women. Tumours
can acquire resistance to these therapies which is a major
obstacle for the successful management of ER positive
tumours.
The calpain family is a group of calcium activated
intracellular cysteine proteases that function in a num-
ber of important cellular processes including, cytoskel-
etal remodelling, cell signalling and both survival and
apoptosis; despite clear roles in a number of importanthis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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functions of calpain, and mechanisms to control proteo-
lytic activity of the enzyme remain to be fully elucidated
(reviewed in [1]). Dysregulation of calpain expression
has been implicated in numerous disease states such as
limb-girdle muscular dystrophy type 2A, Alzheimer’s,
ischemia and cancer. The archetypal members of the
calpain family are calpain-1 (encoded by CAPN1) and
calpain-2 (encoded by CAPN2), and are the most widely
studied due to their ubiquitous expression. Calpain-1
and calpain-2 are composed of different 80 kDa catalytic
subunits and require a common 28 kDa regulatory sub-
unit, calpain-4 (encoded by CAPNS1), to form a hetero-
dimer. Both calpain-1 and calpain-2 can be inhibited by
the endogenous inhibitor calpastatin. Aberrant expres-
sion of calpain family members has been implicated in
tumour progression in a number of cancers and expres-
sion of calpain-1 and calpain-2 in breast cancer has
been shown to be important in patient prognosis [2,3].
In addition to breast cancer, calpain-1 and calpain-2
expression has been shown to be altered in a number of
other tumour types such as ovarian, pancreatic and
gastric [4-6] (reviewed in [7]). The expression of the
archetypical calpains has been implicated in ER signal-
ling, as 17β-oestradiol has been shown to result in
activation of calpain [8], and increased activity has been
shown in ER positive tumours [9].
Calpain-9 (encoded by CAPN9) (also known as nCL-4)
is a more recently charaterised member of the calpain
family that was originally thought to be expressed in a
digestive tract tissue dependent manner. Current
evidence suggests that calpain-9 also associates with
the common 28 kDa regulatory subunit calpain-4 [10],
although co-localisation of calpain-9 and calpain-8
(encoded by CAPN8) (also known as nCL-2) is also
implicated in the gastrointestinal tract [11]. The crystal
structure of mini-calpain-9 compared to that of mini-
calpain-1 suggests that the proteases may act on dif-
ferent substrates and have different mechanisms of
activation. There are few studies on calpain-9 and its
activity and expression in breast cancer; however, in
the breast cancer cell line MCF-7, calpain-9 appears to
have a role in lumen formation [12]. Gene expression
of calpain-9 has been shown to be lowered in gastric can-
cer; however tissue based protein expression showed no
association with survival or pathological variables [4,13].
In murine NIH3T3 fibroblasts knockdown of calpain-9
expression results in cellular transformation, and
tumourigenesis [14]. This study aimed to investigate the
expression of calpain-9 in breast cancer and to determine
links with pathological variables of tumours and patient
prognosis; in particular we aimed to investigate the
importance of calpain-9 in patient subgroups including
those that received endocrine therapy.Methods
Study patients
This study is reported in accordance with REMARK cri-
teria [15] and was approved by Nottingham Research
Ethics committee 2 under the title ‘Development of a mo-
lecular genetic classification of breast cancer’ (REC202313).
This retrospective study utilised 4 μm sections of a tissue
microarray (TMA) consisting of 0.6 mm cores from 783
patients on a poly-L-lysine slides. The cohort was com-
prised of a well characterised group of early stage invasive
breast cancer patients that were treated at Nottingham
University Hospitals, between 1987 and 1998 and had
long term follow-up information available. The median
age of the cohort was 55 years (ranging from 18–72),
59.0% (462/783) of patients had stage I disease, 49.6%
(388/783) of patients had grade 3 tumours, and 50.4%
(395/783) of patients had an intermediate Nottingham
Prognostic Index (NPI) value. Information on clinical
history and outcome is prospectively maintained and
the patients were assessed in a standardised manner for
clinical history and tumour characteristics. Data was
available on a wide range of biomarkers; ER, progester-
one receptor (PgR), HER2 status and lymphovascular
invasion (LVI) determined by immunohistochemistry
were available for this cohort and have been described
previously [16]. Tumours were classified as basal phe-
notype if cytokeratin (CK)-5/6 and/or CK-14 expression
was above 10%. Breast cancer-specific survival was
defined as the time interval between primary surgery to
death from breast cancer in months. Similarly relapse-
free survival was defined as the time interval from pri-
mary treatment to date of disease relapse in months.
Patients were managed in a standard manner, where all
patients underwent a mastectomy or wide local excision,
as decided by disease characteristics or patient choice,
followed by radiotherapy if indicated. Patients received
systemic adjuvant treatment on the basis of Nottingham
Prognostic index (NPI), ER, and menopausal status. Pa-
tients with an NPI score less than 3.4 did not receive
adjuvant treatment and patients with an NPI score of
3.4 or higher were candidates for CMF chemotherapy
(cyclophosphamide, methotrexate and 5-fluorouracil) if
they were ER negative or premenopausal; and endo-
crine therapy if they were ER positive.
Immunohistochemistry
Immunohistochemistry was performed on slides that were
deparaffinised in xylene, followed by rehydration in
ethanol. Antigen retrieval was performed in 0.01 mol L-1
sodium citrate buffer (pH 6) in a microwave: 750 W for
10 minutes, followed by 450 W for 10 minutes. Staining
was achieved using a Novolink Polymer detection kit
(Leica Microsystems, Milton Keynes, UK) according to
the manufacturers’ instructions. Briefly, Peroxidase block
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Tris-buffered saline, and a protein block solution was ad-
ded. Anti-calpain-9 antibody (Abnova, Taipei City, Taiwan;
clone 3A6) was diluted 1:50 and incubated on the tissues
for 24 hours at 4°C. Antibody specificity was demons-
trated using Western blotting (data not shown) and has
been used in other calpain-9 studies [12]. Following anti-
body incubation, the tissues were washed and then subject
to incubation with a post primary solution. Tissues were
then washed and subject to incubation with Novolink
polymer solution. Immunohistochemical reactions were
developed using 3, 3’ diaminobenzidine as the chromoge-
nic substrate and sections were counterstained with
haematoxylin. Following staining, sections were dehy-
drated and fixed in xylene prior to mounting with DPX.
Breast tumour composite sections comprising of tumours
grade 1–3 were included as positive and negative controls.
Staining was examined and scored at 200× magnifica-
tion using immunohistochemical H scoring after scan-
ning of the slides with a Nanozoomer Digital Pathology
Scanner (Hamamatsu Photonics, Hertfordshire, UK).
Staining was assessed as none (0), weak (1), medium (2),
and strong (3) over the percentage area of each staining
intensity. H scores were calculated by multiplying the per-
centage area by the intensity grade (H score range 0–300).
Greater than 30% of cores were scored by a second
assessor blinded to first assessment scores. Single measure
intraclass correlation coefficients between scores for
the TMA was 0.77 showing good concordance bet-
ween scorers.
Statistical analyses
Unbiased high and low protein expression cut-points
were determined using X-Tile software and were deter-
mined prior to statistical analyses [17]. The relationship
between high and low protein expression and clinicopath-
ological variables was assessed using Pearson Chi Square
test of association (χ2). Survival curves were plotted ac-
cording to the Kaplan-Meier method and significanceFigure 1 Representative photomicrographs following immunohistoch
staining. Photomicrographs are shown at 100x magnification with 200x mdetermined using the log-rank test. Multivariate survival
analysis was performed by Cox Proportional Hazards re-
gression model. Spearman rank order correlations were
performed to test associations between proteins. All differ-
ences were deemed statistically significant at the level of
P < 0.05. Statistical analysis was performed using SPSS
21.0 software (IBM, Armonk, USA).
Results
Staining location and frequency
Calpain-9 demonstrated cytoplasmic staining with hetero-
geneity in intensity between adjacent tumour cells ranging
from weak to strong staining. Calpain-9 staining had a
median H-score of 40 and ranged between 0 and 220.
Photomicrographs showing representative staining pat-
terns are shown in Figure 1. A total of 783 breast cancer
specimens were analysed using a tissue microarray; of
which 58.1% (455/783) were invasive ductal carcinomas,
17.0% (133/783) were tubular mixed, 6.5% (51/783) were
classic lobular, all other subcategories accounted for less
than 5% of the studied cohort. Calpain-9 H-scores were
dichotomised using X-Tile software into low and high im-
munoreactivity based on patient survival; X-tile generated
an H score cut point of 40 with 465 (59.4%) cases having a
low score. A proportion of sample cores within the TMA
were unable to be assessed as they were missing or cores
had an insufficient number of tumour cells.
Relationship with clinicopathological variables
The expression of calpain-9 was tested for its association
with a number of clinicopathological variables (Table 1).
Low expression of calpain-9 was significantly associated
with a number of clinicopathological factors, including;
patients over 40 years (χ2 = 5.04, d.f. = 1, P = 0.025),
smaller tumour size (χ2 = 10.67, d.f. = 1, P = 0.001), smaller
tumour stage (χ2 = 9.34, d.f. = 2, P = 0.009), more favou-
rable Nottingham prognostic index (NPI) values (χ2 =
12.96, d.f. = 2, P = 0.002), and ER positive tumours (χ2 =
6.09, d.f. = 1, P = 0.014). No association was observedemical staining of (A) high calpain-9 and (B) low calpain-9
agnification inset box where scale shows 100 μm.
Table 1 The P values are resultant from Pearson χ2 test of association or Fishers Exact when an asterisk is included
Variable Calpain-9 expression in total
patient cohort
Calpain-9 expression in patients that
received endocrine therapy
Low High P value Low High P value
Age
≤40 years 36 (4.6%) 40 (5.1%)
0.025
4 (1.4%) 2 (0.7%)
0.695*
>40 years 429 (54.8%) 278 (35.5%) 160 (54.1%) 130 (43.9%)
Size
≤2 cm 296 (38.0%) 166 (21.3%)
0.001
88 (29.7%) 56 (18.9%)
0.055
>2 cm 166 (21.3%) 151 (19.4%) 76 (25.7%) 76 (25.7%)
Stage
1 294 (37.7%) 168 (21.6%)
0.009
70 (23.6%) 53 (17.9%)
2 128 (16.4%) 115 (14.8%) 73 (24.7%) 64 (21.6%) 0.784
3 39 (5.0%) 35 (4.5%) 21 (7.1%) 15 (5.1%)
Grade
1 87 (11.2%) 48 (6.2%)
0.255
8 (2.7%) 8 (2.7%)
0.4982 155 (19.9%) 101 (13.0%) 53 (17.9%) 50 (16.9%)
3 220 (28.2%) 168 (21.6%) 103 (34.8%) 74 (25.0%)
Nottingham prognostic index
<3.4 158 (20.3%) 71 (9.1%)
0.002
7 (2.4%) 7 (2.4%)
0.9093.4-5.4 219 (28.2) 176 (22.7%) 117 (39.5%) 94 (31.8%)
>5.4 83 (10.7%) 70 (9.0%) 40 (13.5%) 31 (10.5%)
Basal status
Non-basal 351 (46.9%) 240 (46.9%)
0.582
138 (48.6%) 104 (36.6%)
0.257
Basal 90 (12.0%) 68 (9.1%) 20 (7.0%) 22 (7.7%)
ER status
Negative 105 (13.8%) 97 (12.8%)
0.014
26 (9.0%) 29 (10.0%)
0.180
Positive 345 (45.5%) 212 (27.9%) 134 (46.4%) 100 (34.6%)
PgR status
Negative 183 (24.3%) 138 (18.3%)
0.246
64 (22.6%) 51 (18.0%)
0.257
Positive 265 (35.1%) 168 (22.3%) 96 (33.9%) 72 (25.4%)
HER2 status
Negative 394 (51.5%) 264 (34.5%)
0.099
131 (45.5%) 111 (38.5%)
0.765
Positive 55 (7.2%) 52 (6.8%) 26 (9.0%) 20 (6.9%)
Lymphovascular invasion
Negative 255 (36.9%) 168 (26.1%)
0.490
82 (32.2%) 76 (29.8%)
0.164
Positive 127 (19.7%) 94 (14.6%) 59 (23.1%) 38 (14.9%)
Significant P values are indicated by bold. The immunohistochemistry cohort was comprised of 783 patients; however, scores were not available for every patient
for each marker. The number of observations for each marker is shown for each clinicopathological variables and percentage in parentheses. NPI is Nottingham
prognostic index, ER is oestrogen receptor, PgR is progesterone receptor.
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basal-like phenotype tumours, PgR status, HER2 status
or LVI determined by immunohistochemistry.
We further investigated the relationship between the
expression of calpain-9 and the expression of other mem-
bers of the calpain family that had previously been deter-
mined using immunohistochemistry in another study [2].
Calpain-9 expression was not significantly associated withcalpain-1 expression (r2 = 0.04, P = 0.283); but was signifi-
cantly associated with calpastatin expression (r2 = 0.13,
P < 0.001) and calpain-2 expression (r2 = −0.12, P = 0.001),
although with marginal biological relevance.
Relationship with clinical outcome
The expression of calpain-9 in invasive breast cancers
was not associated with overall disease-specific survival
Table 2 Multivariate Cox regression analysis showing
calpain-9 expression, various pathological variables and
their effect upon disease specific survival in patients
treated with endocrine therapy (A) and with an
intermediate NPI value (B)
A
Multivariate cox regression analysis
Sig. Exp(B) 95.0% CI for Exp(B)
Lower Upper
Calpain-9 expression 0.013 0.563 0.358 0.885
Tumour size 0.093 1.556 0.929 2.606
Tumour stage 0.005 2.135 1.258 3.624
Tumour grade 0.081 1.683 0.937 3.021
NPI 0.854 0.927 0.413 2.081
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However, low calpain-9 expression was significantly as-
sociated with adverse survival in patients with an inter-
mediate NPI value (P = 0.009) (Figure 2B), but not in
those patients with a good NPI values (P = 0.918) or poor
NPI values (P = 0.464) (data not shown). Calpain-9 ex-
pression remained significant for overall disease-specific
survival in those patients with an intermediate NPI
score (hazard ratio (HR) = 0.54, 95% confidence inter-
val (95% CI) = 0.36-0.82, P = 0.003). In the multivariate
Cox regression, the potential confounding factors of
PgR status and LVI (with individual Kaplan Meier statis-
tics of P = 0.027 and P < 0.001 respectively) were included
in the analysis (Table 2). Perhaps most interestingly, low
expression of calpain-9 was associated with adverse overallFigure 2 Kaplan-Meier analysis of breast cancer specific
survival showing the impact of low (black line) and high (grey
line) calpain-9 expression in the total patient cohort (A), and
in those patients with an intermediate NPI value (B); with
significance determined using the log-rank test. The numbers
shown below the Kaplan-Meier survival curves are the number of
patients at risk at the specified month.
PgR status 0.204 0.747 0.476 1.172
HER2 status 0.005 2.172 1.270 3.716
LVI status 0.130 1.396 0.906 2.151
B
Multivariate cox regression analysis
Sig. Exp(B) 95.0% CI for Exp(B)
Lower Upper
Calpain-9 expression 0.003 0.543 0.360 0.817
PgR status 0.076 0.705 0.480 1.037
LVI status 0.000 2.474 1.682 3.638
Sig is the P value, Exp(B) is the hazard ratio and 95% CI for Exp(B) is the 95%
confidence interval. Significant P values are indicated in bold.disease-specific survival in those patients that received
endocrine therapy (P = 0.033) (Figure 3B). In multivariate
Cox regression the expression of calpain-9 remained
significant for overall disease-specific survival in those
patients that received endocrine therapy (HR = 0.56,
95% CI = 0.36-0.89, P = 0.013). In the multivariate Cox
regression, the potential confounding factors of tumour
size, tumour stage and grade, NPI status, PgR status,
HER2 status and LVI determined by immunohistochemis-
try (with individual Kaplan-Meier statistics of P < 0.001 for
all variables except tumour size (P = 0.036) and HER2 sta-
tus (P = 0.003)) were included in the analysis (Table 2). In
addition to these prognostic variables, calpain-1, calpain-2
and calpastatin expression were also included in multi-
variate Cox regression, where expression of calpain-9
remained significant for disease specific survival (HR =
0.48, 95% CI = 0.30-0.77, P = 0.002). Calpain-9 expres-
sion was not associated with disease-specific survival of
ER positive patients or patients with basal-like disease.
Relationship with endocrine therapy
Low calpain-9 expression was associated with traditionally
good prognostic markers, however survival of ER positive
breast cancer patients treated with endocrine therapy was
associated with low calpain-9 expression. We therefore
Figure 3 Kaplan-Meier analysis of breast cancer specific
survival showing the impact of low (black line) and high (grey
line) calpain-9 expression in patients that did not receive
endocrine therapy (A), and in those that did receive endocrine
therapy (B); with significance determined using the log-rank
test. The numbers shown below the Kaplan-Meier survival curves
are the number of patients at risk at the specified month.
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patients that received endocrine therapy against their
clinicopathological data (Table 1). No associations were
observed between calpain-9 expression and clinico-
pathological variables.
Discussion
This study investigated the expression of the calpain fam-
ily member calpain-9 in a large consecutive series of early
invasive breast cancer specimens using immunohisto-
chemistry. A total of 37% of patients received endocrine
therapy, including tamoxifen, or a combination of tamoxi-
fen and goserelin acetate. The expression of calpain-9 in
breast cancer has been described in-vitro [12]; however,
this study clearly demonstrates that calpain-9 is expressedin invasive breast cancer and is not expressed solely in a di-
gestive tract specific manner. Low expression of calpain-9
was associated with patients over 40 years, smaller tumour
size and stage, favourable NPI values, and ER positive
tumours.
The calpain system in general has been implicated in
tumour progression, including altering cellular migra-
tion, survival and apoptosis; and expression of calpain-1,
calpain-2 and calpastatin have been shown to be import-
ant in breast cancer [2,3,18]. High calpain-2 expression
in breast cancer is associated with poor survival in pa-
tients with triple negative or basal-like phenotype tu-
mours; and high expression of calpain-1 can predict
response following adjuvant trastuzumab therapy [2,3].
In addition to breast cancer, expression of the calpain
family has been described in a number of solid tumour
types [4-6]. Whilst the current study measured the ex-
pression of calpain-9 it cannot predict the activity of the
enzyme; therefore no conclusions about the effect of
calpain-9 activity can be made as a result of this research.
Expression of calpain-9 was significantly associated with
overall disease-specific survival in those patients with an
intermediate NPI value, whereas it was not associated with
survival in those patients with good or poor NPI values.
Calpain-9 expression remained significant for overall sur-
vival in patients with an intermediate NPI value even
when potential confounding factors were included in the
analysis. The NPI functions to stratify patients’ risk of
5 year recurrence and is used in decision making regard-
ing chemotherapy. It is calculated from the size of the
index lesion, the number of positive lymph nodes and
tumour grade. Patients with a high NPI are offered che-
motherapy, but it is often difficult to determine the best
course of action for those with an intermediate NPI.
Often, in these cases decisions are based on the presence
of other high risk features, such as patient age, tumour
grade, nodal involvement and vascular invasion. Our re-
sults show patients with an intermediate NPI had a signifi-
cantly worse disease-specific survival if their tumours had
low expression of calpain-9, which could be potentially ex-
amined in these patients to aid decision making on sys-
temic treatment. Furthermore, low expression of calpain-9
was associated with adverse disease-specific survival in
those patients that received endocrine therapy. Expression
of calpain-9 remained significant for disease-specific sur-
vival in this sub group of patients even when potential
confounding factors were included in the analysis. There
was no association between expression of calpain-9 and
disease-specific survival in ER positive patients or patients
with basal-like disease. Endocrine therapy is often offered
to patients with ER positive disease perceived to have low
risk disease on traditional clinicopathological features
such as tumour stage and grade, NPI and nodal status.
Most tumours that initially respond to endocrine therapies
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successful management of ER positive tumours. Interest-
ingly, although tumours become resistant to endocrine
therapy, they can still retain ER expression (reviewed in
[19]). The expression of calpain family members has been
implicated in ER signalling. An increase in calpain activity
has been shown following treatment with 17β-oestradiol,
but also in ER positive tumours [8,9]. There are limited
direct reports of ER modulating calpain-9 expression or
activity. In lacrimal glands from mice which were treated
with 17β-oestradiol and/or progesterone to determine dif-
ferentially expressed mRNAs, CAPN9 was shown to be
down regulated [20]. Calpain-8 has been shown to be
stimulated by 17β-oestradiol in the pituitary, with the
calpain-8 promoter containing an oestrogen response
element [21].
An interesting observation of this study is that low
calpain-9 expression is associated with disease-specific sur-
vival, whereas high expression of calpain-1 and calpain-2
are associated with poor breast cancer prognosis in other
studies [2,3]. The implications of this observation are
unclear. Low CAPN9 expression has been observed in
gastric cancer; however protein expression of calpain-9
within the tissue showed no association with survival or
pathological variables [4,13]. Interestingly, low calpain-
9 expression was associated with adverse survival in
breast cancer patients treated with endocrine therapy,
whereas low expression of calpain-9 was associated with
markers of good prognosis in the total patient cohort. To
investigate this further we determined the relationship be-
tween calpain-9 expression and clinicopathological vari-
ables in those patients treated with endocrine therapy and
did not see the same associations. Similar findings were
observed for calpain-9 expression in those patients with
intermediate NPI values (data not shown). It is unclear
why low calpain-9 expression is associated with favourable
prognostic factors in the total patient cohort, but with
adverse disease-specific survival of patients treated with
endocrine therapy.
Conclusions
This study has demonstrated that the expression of
calpain-9 is associated with important clinicopathologi-
cal variables, and that expression is associated with
disease-specific survival in sub-groups of patients. The
expression of calpain-9 was associated with disease-
specific survival in patients with an intermediate NPI
value, and in those patients that received endocrine
therapy. As part of future research, these results require
validation in multi-centre cohorts of breast cancer pa-
tients to determine the clinical utility of measuring
calpain-9 expression as an indicator of response to
endocrine therapy or in those patients with an inter-
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